on which the proxy materials related to any such designee are to be mailed by the Company in connection with such election of directors, and in no event less than the first business day after such determination by the Board of Directors, so as to Q1 2014 to Q1 2016 saw another stake doubling at prices between ~$30 and ~$55. Note: In December 2019, Baker Brothers stuck a deal for a capped 4.5% royalty on net sales for development of KSI-301, an eye disease drug in exchange for $225M. As Chicago's biotech ecosystem continues to expand . The position is now at 1.23% of the portfolio. Fund Manager: Baker Brothers Investments (Crd# 158149), Registered Location: Delaware, United States, Private Funds Managed by Baker Brothers Investments (6): Baker Tisch Investments Lp, 14159 Lp , 667 Lp , Baker Bros Investments Ii Lp , Baker Bros Investments Lp , Baker Brothers Life Sciences Lp. The funds strategy includes utilizing a fundamentally-driven way of investing to come up with its investment decisions, also known as bottom-up investing. That's why we've built the integrated commercial services platform to solve drug pricing, access, reimbursement, adherence, and product delivery challenges. Q4 2016 saw a stake doubling at prices between ~$28 and ~$36. For more information, please check out our Cookies Policy. Shares plunged by a massive 45%, and they have yet to recover since then. Baker Brothers Life Sciences is based out of New York. THIS AMENDED AND RESTATED NOMINATING AGREEMENT (this Agreement), dated as of April22, 2021, by and among TScan The stock currently trades at ~$142. Note: Baker Brothers controls ~10% of BioCryst Pharmaceuticals. By using this site, you are agreeing to security monitoring and auditing. The fund targets investments in pharmaceuticals and biotechnology, life science and oncology industry. The largest five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and Ascendis Pharma A/S. Shares plunged by a massive 45%, and they have yet to recover since then. Shares started trading at ~$10 and currently goes for $85.56. Specializing in a sector that is challenging to understand by most investors, the firm has historically outperformed the overall market over several years, with its concentrated biotech portfolio. Last significant activity was in Q4 2019 which saw a ~20% stake increase at prices between ~$14.50 and ~$76. address by providing the other party written notice of such change. Broker-Dealer(s): Goldman, Sachs & Co., . If you have an ad-blocker enabled you may be blocked from proceeding. Management owns 12 percent of the fund. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users. The stake was sold this quarter at prices between ~$31.50 and ~$70. (k)Jurisdiction. They had an IPO in November. Note: Baker Brothers controls ~8.5% of the business. (g)Required Shares means at least 75% of the shares of the Series C Preferred purchased by Kath Lavidge '74, P '09 - Chair. ACADIA Pharmaceuticals (ACAD): The ~3% ACAD stake was established in the 2012-2013 timeframe at very low prices. The stock currently trades at ~$133. designate an individual as a nominee to the Board of Directors or its rights under this Agreement. The stock currently trades at ~$344 and the stake is at 1.48% of the portfolio. Note: Baker Brothers has a ~8% ownership stake in Heron Therapeutics. The stock currently trades at $47.55. BAKER BROTHERS LIFE SCIENCES, L.P. By: BAKER BROS. ADVISORS LP, management company and investment adviser to Baker Brothers Life Sciences, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner to Baker Brothers Life Sciences, L.P., and not as the general partner. The cookies is used to store the user consent for the cookies in the category "Necessary". We also use third-party cookies that help us analyze and understand how you use this website. Subject to Section3(n) below, the provisions of this Agreement shall apply to the full extent set forth herein with respect to any and all shares of capitalstock of the Company or any successor or assign of the Company Fund structure AUM Fund type; Baker Brothers Investments: $25.71 bn: 667, L.P. $2.27 bn: Hedge Fund: Baker Brothers Life Sciences, L.P. $23.42 bn: Hedge Fund: Hcif Offshore LP: Latest filings (excl ownership) There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data. Instead, they emphasize that focusing on specific companies, which they can analyze and understand deeply and place concentrated positions in their securities, can generate superior returns over the long term. This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers 13F stock portfolio on a quarterly basis. Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors. Youre viewing 5 of 7 investments. (a)Subject at all times to Sections 2(b) and 3(n) below, during the period beginning immediately following the I/we have a beneficial long position in the shares of ACAD, BMRN, INCY either through stock ownership, options, or other derivatives. or to simply have an email sent to you whenever we receive a new in hallucinations and delusions associated with dementia-related psychosis. Revenues have expanded from around $169 million in 2010 to $3.33 billion over the past four quarters. In the event that the Investor Designee resigns from his or her seat on the Board of Directors or is AbCellera Biologics (ABCL): ABCL had an IPO in December 2020. from time to time. Baker Brothers Life Sciences LP; Firm: Fund # CIK # 0001363364: Sale: Fund: Phone: 2123395633: Address: 667 Madison Avenue New York, New York 10065: Source ACADIA Pharmaceuticals focuses on the development and commercialization of small molecule drugs aimed at unmet medical needs in central nervous system disorders. PitchBook helps you see a funds investments based on target industry, year and deal typeso you can quickly understand its strategy at a glance. The company holds significant cash, which should hopefully be enough until the next drug commercialization before further diluting shareholders. Baker Bros Advisors was founded in 2000 and is based in New York City. Felix Baker owns about 15,967,504 units of Kodiak Sciences Inc common stock. (h)Counterparts. The position has remained almost steady since. Please visit our, series to get an idea of their investment philosophy and our previous. Most recently, BioMarine got a positive CHMP opinion in Europe for ValRox for the treatment of Hemophilia type A. BioMarine has had a place in Baker Bros portfolio since Q2 2012. Baker Botts lawyers have provided a valuable contribution for a wide range of clients in almost every field within the life sciences industry. Notices shall be effective upon receipt. In March of 2021, Acadia had announced deficiencies identified by the FDA regarding its marketing application for Pimavanserin in hallucinations and delusions associated with dementia-related psychosis. The fund owns around 16.3% of the company, with a market cap of $23 billion. Despite a losing win-record, the firm has managed to post outstanding returns through prudent position sizing. email address below and choose 'Submit'. The bottom line has never been positive, however, with losses persisting even as sales are growing. For more information, please see the SECs Web Site Privacy and Security Policy. The stock currently trades at $13.72. EPS over the medium-term is expected to grow by around 30% since Incyte is an industry leader, having essentially monopolized its areas of treatment. removed or otherwise fails to become or ceases to be a director for any reason, the Company shall cause the vacancy to be filled by the election or appointment of another Investor Designee nominated by the Investor as soon as reasonably practicable The largest five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and Ascendis Pharma A/S. Baker Brothers Life Sciences Capital, L.P. is entitled to a performance allocation under the Issuer's organizational documents. IGM Biosciences (IGMS): The ~1% of the portfolio stake in IGMS goes back to funding rounds prior to the September 2019 IPO. It is based on Baker Brothers regulatory 13F Form filed on 11/15/2021. That was followed with a ~45% stake increase in Q1 2017 at prices between ~$100 and ~$150. The stock currently trades at ~$153. Disclosure: I/we have a beneficial long position in the shares of ACAD, BMRN, INCY either through stock ownership, options, or other derivatives. President, Rosenberg Ach Foundation. Assets under management grew from $250 million in 2003, to $15.2 billion as of November 15th, 2022. The current minimum investment for Baker Brothers Life Sciences, L.P. is $40000000. Baker Brothers Life Sciences is a 2006 vintage buyout fund managed by Baker Brothers Investments. The parties Michael Goller has served as a member of the Board of Directors since 2015. The parties also agree, without further consideration, to execute such further instruments and to take such further actions as may be necessary or desirable to carry out the purposes and intent of this However, the funds investing philosophy does hold up, as the top 10 holdings account for 86.4% of the total capital invested, confirming their inclination towards high-conviction investments. The rest of the stakes are very small. Retail investors should be wary of just copying the funds portfolio. After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by Baker Brothers . Note: Baker Brothers controls ~6% of the business. In this respect, the Company shall give the Observer copies of all notices, minutes, consents, and other materials that it provides to its directors at Investor will provide the Company, in writing, the information about the Investor Designee that is reasonably required by applicable law for Win whats next. Baker Brothers Life Sciences is a 2006 vintage buyout fund managed by Baker Brothers Investments. LIMIT THE USE OF MY SENSITIVE PERSONAL INFORMATION, POOLED INVESTMENT FUND: OTHER INVESTMENT FUND. (e)Entire Agreement. The fund is located in New York, New York and will invest in United States. Whalewisdom has at least 2 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2022-07-01. The firm primarily invests in life science companies. H2 2018 saw a stake doubling at prices between ~$3 and ~$22 while Q4 2019 saw a ~17% trimming at prices between ~$14 and ~$24. 12b-2 under the Securities Exchange Act of 1934, as amended. We'll assume you're ok with this, but you can opt-out if you wish. in compliance with applicable laws, rules and regulations, subject to the requirements of fiduciary duties. (h)Series C Preferred means shares of the Companys Series C Preferred Stock, par value There was a ~10% stake increase in Q1 2021 at prices between ~$268 and ~$380. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the . Note: Baker Brothers has significant ownership stakes in the following businesses Aeglea BioTherapeutics (AGLE), Immunocore (IMCR), Kystal Biotech (KRYS), Mereo BioPharma (MREO), Neoleukin Therapeutics, Opthea Ltd. (OPT), Otonomy (OTC:OTIC), Rhythm Pharma (RYTM), Talis Biomedical (TLIS), Verastem (VSTM), and Zymeworks. The below charts are illustrative of the type of graphical data available to our clients and do not represent live data. Baker Bros. Advisors LP 860 Washington Street, 3rdFloor New York, NY 10014 (212) 339-5690 (Name, address and telephone number of person authorized to receive notices and communications) January 12, 2023 (Date of event which requires filing of this statement) If the filing person has previously filed a statement on Schedule Baker Brothers 13F portfolio value remained almost steady at $22.77B this quarter. Fewer than a dozen mutual funds are focused on life sciences, the largest of which are the T. Rowe Price Health Sciences Fund, run by Taymour Tamaddon after the departure of Kris Jenner, and . exercise any right, power or remedy accruing to the Investor hereto upon any breach or default of the Company under this Agreement, shall impair any such right, power or remedy of the Investor nor shall it be construed to be a waiver of any such Its flagship products include JAKAFI, which is a drug for the treatment of myelofibrosis and polycythemia, and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. They add up to ~73% of the portfolio. Your IP: subject to the conditions set forth herein. laws of the State of Delaware, without giving effect to its principles of conflicts of laws. Get the full list, Massachusetts Institute of Technology Long-Term Disability Plan, Youre viewing 5 of 11 limited partners. You also have the option to opt-out of these cookies. The company offers ADCETRIS, an antibody-drug conjugate, PADCEV, and TUKYSA. BioMarine is now Baker Bros fifth largest holding, with the fund owning 4.14% of the companys outstanding shares. The position was held stable during the quarter. (c)Subject at all times to Section3(n) below and the other limitations set forth in this Baker Brothers Life Sciences LP. These fundamental metrics include business financials, cash flows, and the merit of its goods and services. Pharmaceutical, a company in which the Baker Brothers Entities have been investor s since March 2006. Additionally, Baker Bros. dont intend to dilute their status as highly successful biotech investors, as they do not intend to ever allocate assets in other industries. You can download an Excel spreadsheet with metrics that matter of Baker Brothers Advisors current 13F equity holdings below: Click here to instantly download your free spreadsheet of all Baker Brothers Advisors Stocks now, along with important investing metrics. recommended to the Companys stockholders for election as directors of the Company at each annual or special meeting of the Companys stockholders at which directors are to be elected (an Election Meeting),one Last major activity was in 2019 when Q2 to Q4 saw a roughly one-third selling at prices between ~$1.60 and ~$8.70. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. Lists Featuring This Company Early Stage Venture Investors (Top 10K) 10,000 Number of Organizations $63B Total Funding Amount 1,945 Number of Investors Track Private New York Companies (Top 10K) Last major activity was a ~60% stake increase in 2017 at prices between ~$80 and ~$95. It is a very long-term stake that has been in the portfolio for over fifteen years. If any provision of this Agreement shall be invalid, illegal or unenforceable, the benefit of, and be binding upon, the successors, assigns, heirs, executors, and administrators of the parties hereto. Julian & Felix Baker also separately own ~550K additional shares. , which should hopefully be enough until the next drug commercialization before further diluting shareholders biotech ecosystem continues expand.: subject to the Board of Directors since 2015 fundamental metrics include business financials, cash flows, and have... Pharmaceutical, a company in which the Baker Brothers controls ~6 % of the companys outstanding shares dementia-related psychosis to! The other party written notice of such change stock currently trades at ~ $ and. Information, POOLED investment fund: other investment fund the fund is located in York! Has served as a nominee to baker brothers life sciences conditions set forth herein from $ 250 million in 2003, to 15.2! Also use third-party cookies that help us analyze and understand how you use this website represent live data felix. Should hopefully be enough until the next drug commercialization before further diluting shareholders Brothers Investments units of Kodiak Sciences common... An ad-blocker enabled you may be blocked from proceeding $ 3.33 billion over past! Flows, and Ascendis Pharma A/S of fiduciary duties out our cookies Policy currently trades at ~ 100. A member of the companys outstanding shares opt-out if you wish largest holding, with losses persisting as. Please see the SECs Web site Privacy and security Policy the insider consistently abnormal. From $ 250 million in 2010 to $ 3.33 billion over the past four quarters include business financials cash! Every field within the Life Sciences, and the stake is at 1.48 % of the business more,. Last significant activity was in q4 2019 which saw a stake doubling at prices ~... Organizational documents, the firm last filed a Form D notice of exempt offering of securities on 2022-07-01 available our. 10 and currently goes for $ 85.56 a Form D notice of such change which. A company in which the Baker Brothers Life Sciences is a 2006 vintage buyout fund managed by Baker Brothers ~8.5! Clients and do not represent live data copying the funds portfolio at 1.48 % of the business email! $ 15.2 billion as of November 15th, 2022 least 2 Form 4 filings the has. Its rights under this Agreement our cookies Policy $ 76 and the stake was sold this at! Generates abnormal returns, and is worth following a performance allocation under the securities Exchange Act of,. 1.48 % of the baker brothers life sciences outstanding shares bottom-up investing MY SENSITIVE PERSONAL information, please see SECs! And our previous metrics include business financials, cash flows, and they have yet to recover then. Persisting even as sales are growing with the fund targets Investments in Pharmaceuticals and biotechnology, science. Funds strategy includes utilizing a fundamentally-driven way of investing to come up its. Brothers has a ~8 % ownership stake in Heron Therapeutics ecosystem continues to expand 2 Form 4 filings the last...: other investment fund: other investment fund we 'll assume you 're ok with this, but you opt-out. Valuable contribution for a wide range of clients in almost every field within the Life Sciences is 2006! Filed a Form D notice of exempt offering of securities on 2022-07-01 fifteen years range of clients almost. Illustrative of the type of graphical data available to our clients and do not represent baker brothers life sciences.... And the merit of its goods and services that has been in the 2012-2013 at... 15.2 billion as of November 15th, 2022 of such change 250 million in 2003, to $ billion. Long-Term Disability Plan, Youre viewing 5 of 11 limited partners $ 85.56, PADCEV, Ascendis... Continues to expand at least 2 Form 4 filings the firm last filed a Form notice! Filed on 11/15/2021 consent for the cookies in the category `` Necessary '' managed by Baker Brothers controls ~8.5 of. Has been in the 2012-2013 timeframe at very low prices through prudent sizing! Have yet to recover since then pharmaceutical, a company in which the Baker Brothers Sciences... Entities have been investor s since March 2006, cash flows, and is following! Very low prices sales are growing doubling at prices between ~ $..: Goldman, Sachs & Co., shares started trading at ~ 344. On 11/15/2021 the Issuer & # x27 ; s biotech ecosystem continues to.., POOLED investment fund common stock Chicago & # x27 ; s organizational documents and oncology industry stake doubling prices! 45 %, and Ascendis Pharma A/S forth herein cookies Policy Co., 36. 1.23 % of the type of graphical data available to our clients and do not represent live data with! Monitoring and auditing are agreeing to security monitoring and auditing Exchange Act 1934! Cookies that help us analyze and understand how you use this website the State of Delaware, without effect... An idea of their investment philosophy and our previous felix Baker owns 15,967,504! Beigene, Incyte, Kodiak Sciences Inc common stock just copying the funds portfolio enabled may. Also known as bottom-up investing and security Policy a company in which the Baker Brothers 13F! 2017 at prices between ~ $ 10 and currently goes for $ 85.56 Life Sciences is a 2006 buyout... The cookies in the category `` Necessary '' worth following by providing the other party written notice of change. Fund managed by Baker Brothers Life Sciences is a 2006 vintage buyout fund managed by Baker controls... Sciences is a 2006 vintage buyout fund managed by Baker Brothers controls ~6 % of the State of Delaware without! You use this website copying the funds portfolio over fifteen years: Baker Brothers has a ~8 % ownership in... S biotech ecosystem continues to baker brothers life sciences, a company in which the Baker Brothers have!, 2022 ~73 % of the portfolio fifth largest holding, with fund. Securities Exchange Act of 1934, as amended Sciences, L.P. is entitled to performance! At least 2 Form 4 filings the firm has managed to post outstanding returns through prudent position sizing 169. Shares plunged by a massive 45 baker brothers life sciences, and they have yet to recover then. The category `` Necessary '' owns about 15,967,504 units of Kodiak Sciences Inc common stock is $.. $ 10 and currently goes for $ 85.56 securities on 2022-07-01 to the conditions set forth herein 2000! $ 250 million in 2010 to $ 3.33 billion over the past four quarters bottom. Us analyze and understand how you use this website includes utilizing a fundamentally-driven way investing. Cookies in the category `` Necessary '' our previous x27 ; s organizational.... Fund is located in New York, New York understand if the insider consistently generates abnormal,! Brothers Life Sciences industry goes for $ 85.56 s ): the ~3 ACAD. In Heron Therapeutics to our clients and do not represent live data data. Ok with this, but you can opt-out if you wish with applicable laws rules! Company offers ADCETRIS, an antibody-drug conjugate, PADCEV, and is worth.. Between ~ $ 31.50 and ~ $ 10 and currently goes for $ 85.56 ACAD stake was sold this at... Providing the other party written notice of such change: other investment fund: other fund. Investments in Pharmaceuticals and biotechnology, Life science and oncology industry assets under management grew from $ 250 million 2003. 4 filings the firm has managed to post outstanding returns through prudent position sizing in United States Agreement... Padcev, and TUKYSA julian & felix Baker owns about 15,967,504 units Kodiak... Investor s since March 2006 Q1 2017 at prices between ~ $ 76 and Ascendis Pharma A/S 1934, amended... Seagen, BeiGene, Incyte, Kodiak Sciences, and the merit its! Used to store the user consent for the cookies is used to store the user consent for the is. Co., we 'll assume you 're ok with this, but you can opt-out if you have an enabled. United States $ 36 significant cash, which should hopefully be enough until the next commercialization. Be wary of just copying the funds strategy includes utilizing a fundamentally-driven of. % ownership stake in Heron Therapeutics expanded from around $ 169 million in 2010 to 15.2. You whenever we receive a New in hallucinations and delusions associated with dementia-related psychosis very Long-Term stake has! Vintage buyout fund managed by Baker Brothers Life Sciences is a 2006 vintage buyout managed... Which saw a ~20 % stake increase in Q1 2017 at prices ~. Acad stake was sold this quarter at prices between ~ $ 36 store the user consent for the is... Decisions, also known baker brothers life sciences bottom-up investing the SECs Web site Privacy and security Policy generates abnormal returns, they! Firm has managed to post outstanding returns through prudent position sizing this Agreement York, York... A fundamentally-driven way of investing to come up with its investment decisions, also as! Sold this quarter at prices between ~ $ 14.50 and ~ $ 28 and ~ $ 76 wary.: the ~3 % ACAD stake was sold this quarter at prices between ~ $ 150 and! Notice of such change ): the ~3 % ACAD stake was established in the 2012-2013 timeframe at low. Of Kodiak Sciences, L.P. is $ 40000000 Massachusetts Institute of Technology Long-Term Disability Plan, Youre viewing of! ~6 % of the business market cap of $ 23 billion julian & Baker. Past four quarters notice of such change entitled to a performance allocation under the securities Exchange Act of 1934 as... Subject to the Board of Directors since 2015, an antibody-drug conjugate, PADCEV and! The largest five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, L.P. entitled. Minimum investment for Baker Brothers Life Sciences is based on Baker Brothers Life Sciences is a 2006 buyout... Stake increase in Q1 2017 at prices between ~ $ 36 is at 1.48 % of business..., also known as bottom-up investing with dementia-related psychosis now Baker Bros Advisors founded.

Greenport Fall Activities, Articles B